Analyzing how Dendritic Cells Interact with Synthetic Virus-Like Particle Vaccines | Imaris

Analyzing how Dendritic Cells Interact with Synthetic Virus-Like Particle Vaccines

Immunology

Drs. Kenneth C. McCullough and Rajni Sharma, Institute of Virology and Immunoprophylaxis; Dr. Arin Ghasparian and Professor John A. Robinson, University of Zürich

Researchers from the Institute of Virology and Immunoprophylaxis and the University of Zürich, both in Switzerland, are using Imaris software to better understand interactions between dendritic cells and nanoparticulate vaccines. The nanoparticulate vaccines under study are based on synthetic virus-like particles and can efficiently induce adaptive immunity without the adjuvant usually required to enhance the recipient’s immune response. Dendritic cells are crucial for initiating and directing immune responses; understanding how synthetic virus-like particles interact with dendritic cells in vitro would provide important information that could be used to develop an efficacious vaccine in vivo.

Figure (A) Synthetic virus-like particles (SVLP, green) co-localised with cholera toxin B (CTB, red) in lipid rafts, as well as association with CD9 (blue) containing rafts. The image shown is a Blend format. Figure (B) Once internalised, the SVLPs (green) remain peripheral, but associated with microtubules (red) extended into the region of the lamellipodium. These SVLP-containing vesicles remain distinct from the Major Histocompatibility Complex (MHC) Class II+ structures (blue). The image shown is a MIP (max) format, with the microtubules enhanced using the Filament Tracer module, and the SVLP-vesicles and MHC Class II-vesicles enhanced using the Spots module. Images courtesy of Kenneth C. McCullough.

The researchers are investigating how dendritic cells detect nanoparticulate vaccines, together with the roles played by particular cell receptors and the variety of endocytic processes associated with dendritic cells. In this study, they examined a nanoparticulate vaccine derived from synthetic lipopeptides that self-assemble into synthetic virus-like particles. The lipopeptides carry antigenic determinants that are reactive with B- and T- lymphocytes, and the vaccine can also be constructed to carry pathogen-associated molecular patterns that activate the dendritic cells.

The researchers imaged the interaction of dendritic cells with synthetic virus-like particles using a confocal scanning microscope and then analysed these images using Imaris. The Imaris software permitted a defined analysis and visual description of how dendritic cells endocytosed synthetic virus-like particles. “The Imaris software allowed accuracy of co-localisation through application of the co-localisation module, which gave both mathematical readouts and visual identification of co-localised voxels within the cellular structures,” Dr. McCullough says. “High definition of the visual description obtained for dendritic cell endocytosis of synthetic virus-like particles, and the associated cellular structures, was made possible through the powerful Filament Tracer module and by 3D visualization using Surface and Spots rendering

Figure (C) The peripheral SVLP-vesicles (green) co-localised with high molecular weight dextran-containing structures (red), demonstrating an association with macropinosomes (high molecular weight dextran accumulates in macropinosomes). They remained relatively peripheral behind the lamellipodium (depicted by the more intense and solid white/grey stain obtained using acquisition with Trans and image analysis with the Surface module), and distinct from the MHC Class II+ vesicles. The SVLP/dextran-vesicles (green/red/yellow) and MHC Class II-vesicles (blue) were enhanced using the Spots module, with the dextran Spots partially opaque to enhance visualisation of the green SVLPs with the red dextran; the whole image shown is a Normal Shading format. Figure (D) Peripheral SVLP-vesicles (green) observed at an earlier stage than in (C), co-localised with CTB (red) to show the GM-1 ganglioside lipid raft origin of the endocytic vesicles; at this earlier stage, the SVLP-vesicles have not yet co-localised with the macropinosomes in which high molecular weight dextran (blue) had accumulated. The application of the Surface module was as in (C), and the Spots module was applied to the SVLP/CTB-vesicles and dextran+ macropinosomes; the whole image shown is a Normal Shading format. Images courtesy of Kenneth C. McCullough.

The image analysis revealed details about the endocytic processes. They observed rapid interaction of the synthetic virus-like particles with the cell surface and slow internalisation involving GM-1 ganglioside-containing lipid rafts, polarizing to the leading edge of the cells. Structures containing the synthetic virus-like particles remained in peripheral intracellular locations for long periods, while slowing interacting with early endosomes and then macropinosomes. “Such characteristics of slow processing and retention in macropinosomes are important for the efficient processing of antigen for presentation to the adaptive immune system and stimulation of efficacious adaptive immune responses, relating to our current knowledge on how dendritic cells operate,” Dr. McCullough says. “This was reflected in the capacity of the synthetic virus-like particles to induce both humoral and cell-mediated immune responses in vivo, in murine and porcine models.”

Research Paper: Sharma R, Ghasparian A, Robinson JA, McCullough KC (2012) Synthetic Virus-Like Particles Target Dendritic Cell Lipid Rafts for Rapid Endocytosis Primarily but Not Exclusively by Macropinocytosis. PLoS ONE 7(8): e43248. doi:10.1371/journal.pone.004324.

Multimedia Library
Application Images (4)
Publications Database
Caveolin-1 deficiency induces a MEK-ERK1/2-Snail-1-dependent epithelial–mesenchymal transition and fibrosis during peritoneal dialysis
The chemokine receptors ACKR2 and CCR2 reciprocally regulate lymphatic vessel density
Host DNA released in response to aluminum adjuvant enhances MHC class II-mediated antigen presentation and prolongs CD4 T-cell interactions with dendritic cells
Three-Dimensional Visualization of the Mouse Thymus Organization in Health and Immunodeficiency
Molecular and functional evidence of HCN4 and caveolin-3 interaction during cardiomyocyte differentiation from human embryonic stem cells
Shigella impairs T lymphocyte dynamics in vivo
Constitutive Lymphocyte Transmigration across the Basal Lamina of High Endothelial Venules Is Regulated by the Autotaxin/Lysophosphatidic Acid Axis
Sphingosine-1-phosphate-mediated osteoclast precursor monocyte migration is a critical point of control in antibone-resorptive action of active vitamin D
Opposing chemokine gradients control human thymocyte migration in situ
Motile invaded neutrophils in the small intestine of Toxoplasma gondii-infected mice reveal a potential mechanism for parasite spread
In vivo imaging of CD8+ T cell-mediated elimination of malaria liver stages
Chemokine Receptor CXCR6-Dependent Hepatic NK T Cell Accumulation Promotes Inflammation and Liver Fibrosis
Tetraspanin CD37 contributes to the initiation of cellular immunity by promoting dendritic cell migration
Perivascular Mast Cells Dynamically Probe Cutaneous Blood Vessels to Capture Immunoglobulin
Rgs13 Constrains Early B Cell Responses and Limits Germinal Center Sizes
Elimination of Self-Reactive T Cells in the Thymus: A Timeline for Negative Selection
NLRP10 is a NOD-like receptor essential to initiate adaptive immunity by dendritic cells
Expansion of Cortical and Medullary Sinuses Restrains Lymph Node Hypertrophy during Prolonged Inflammation
Replication-Competent Influenza A Virus That Encodes a Split-Green Fluorescent Protein-Tagged PB2 Polymerase Subunit Allows Live-Cell Imaging of the Virus Life Cycle
MT1-MMP regulates the PI3K (delta) Mi-2/NuRD-dependent control of macrophage immune function

Sign up for the Bitplane Newsletter!

Receive articles like this one, release notes, product launches, press releases and more with our regular newsletter. It's free to subscribe, will be sent every 6 weeks, and you can opt out at any time.

NAME
EMAIL


Try Imaris FREE for 10 days?